BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19152679)

  • 1. A universal assay for detection of oncogenic fusion transcripts by oligo microarray analysis.
    Skotheim RI; Thomassen GO; Eken M; Lind GE; Micci F; Ribeiro FR; Cerveira N; Teixeira MR; Heim S; Rognes T; Lothe RA
    Mol Cancer; 2009 Jan; 8():5. PubMed ID: 19152679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays.
    Jhavar S; Reid A; Clark J; Kote-Jarai Z; Christmas T; Thompson A; Woodhouse C; Ogden C; Fisher C; Corbishley C; De-Bono J; Eeles R; Brewer D; Cooper C
    J Mol Diagn; 2008 Jan; 10(1):50-7. PubMed ID: 18165275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
    Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
    Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
    Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
    Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia.
    Gabriel AS; Lafta FM; Schwalbe EC; Nakjang S; Cockell SJ; Iliasova A; Enshaei A; Schwab C; Rand V; Clifford SC; Kinsey SE; Mitchell CD; Vora A; Harrison CJ; Moorman AV; Strathdee G
    Epigenetics; 2015; 10(8):717-26. PubMed ID: 26237075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
    Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA
    Neoplasia; 2006 Jun; 8(6):465-9. PubMed ID: 16820092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
    Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
    Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer.
    Soller MJ; Isaksson M; Elfving P; Soller W; Lundgren R; Panagopoulos I
    Genes Chromosomes Cancer; 2006 Jul; 45(7):717-9. PubMed ID: 16575875
    [No Abstract]   [Full Text] [Related]  

  • 11. Delineation of TMPRSS2-ERG splice variants in prostate cancer.
    Hu Y; Dobi A; Sreenath T; Cook C; Tadase AY; Ravindranath L; Cullen J; Furusato B; Chen Y; Thangapazham RL; Mohamed A; Sun C; Sesterhenn IA; McLeod DG; Petrovics G; Srivastava S
    Clin Cancer Res; 2008 Aug; 14(15):4719-25. PubMed ID: 18676740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.
    Smit FP; Salagierski M; Jannink S; Schalken JA
    BJU Int; 2013 May; 111(5):836-42. PubMed ID: 23578236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
    Tomlins SA; Rhodes DR; Perner S; Dhanasekaran SM; Mehra R; Sun XW; Varambally S; Cao X; Tchinda J; Kuefer R; Lee C; Montie JE; Shah RB; Pienta KJ; Rubin MA; Chinnaiyan AM
    Science; 2005 Oct; 310(5748):644-8. PubMed ID: 16254181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A sensitive array-based assay for identifying multiple TMPRSS2:ERG fusion gene variants.
    Lu Q; Nunez E; Lin C; Christensen K; Downs T; Carson DA; Wang-Rodriguez J; Liu YT
    Nucleic Acids Res; 2008 Nov; 36(20):e130. PubMed ID: 18794177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
    Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
    Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing.
    Pflueger D; Terry S; Sboner A; Habegger L; Esgueva R; Lin PC; Svensson MA; Kitabayashi N; Moss BJ; MacDonald TY; Cao X; Barrette T; Tewari AK; Chee MS; Chinnaiyan AM; Rickman DS; Demichelis F; Gerstein MB; Rubin MA
    Genome Res; 2011 Jan; 21(1):56-67. PubMed ID: 21036922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.
    Dong J; Xiao L; Sheng L; Xu J; Sun ZQ
    Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data.
    Rouzier C; Haudebourg J; Carpentier X; Valério L; Amiel J; Michiels JF; Pedeutour F
    Cancer Genet Cytogenet; 2008 May; 183(1):21-7. PubMed ID: 18474293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.
    Paulo P; Barros-Silva JD; Ribeiro FR; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
    Genes Chromosomes Cancer; 2012 Mar; 51(3):240-9. PubMed ID: 22081504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Truncated ERG proteins affect the aggressiveness of prostate cancer.
    Wu F; Ding S; Lu J
    Med Hypotheses; 2013 Apr; 80(4):490-3. PubMed ID: 23357671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.